| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9261 | Nelarabine | Arranon | 50 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 2005 | Jan 1, 2007 | In Use | ||
| C9240 | ixabepilone | Ixempra | 1mg | Chemotherapy | Antitumor Antibiotic | Epothilones | No | 2007 | Jan 1, 2008 | Dec 31, 2013 | No Longer Used | |
| Q2048 | Doxorubicin | Doxil | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1995 | Jul 1, 2012 | Dec 31, 2013 | No Longer Used | |
| NA | Alpelisib | Piqray | 200mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2019 | In Use | |||
| C9078 | Trilaciclib | Cosela | 1mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDX 4/6 | No | 2021 | Jul 23, 2021 | Sep 27, 2021 | No Longer Used | |
| NA | Avapritinib | Ayvakit | 300mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
| J9054 | Bortezomib (boruzu) | Boruzu | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2024 | Mar 26, 2025 | In Use | ||
| NA | Panobinostat | Farydak | 10 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
| J9052 | Carmustine (Accord) | Carmustine | 100mg | Chemotherapy | Alkylating Agent | Nitrosurea | No | 2022 | Dec 7, 2023 | In Use | ||
| NA | Erlotinib | Tarceva | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2004 | In Use | |||
| J9208 | Ifosfamide | Ifosfamide | 1 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1988 | Jan 1, 1999 | In Use | ||
| NA | Cabozantinib | Cabometyx | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| C9433 | Thiotepa | Tepadina | 15 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | No | 1959 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
| NA | Abemaciclib | Verzenio | 200 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
| J7527 | Everolimus | Afinitor, Afinitor Disperz | 0.25 mg | Chemotherapy | Enzyme Inhibitor | mTOR | Yes | 2009 | Jan 1, 2013 | In Use | ||
| J8561 | Everolimus | Afinitor, Afinitor Disperz | 0.25 mg | Chemotherapy | Enzyme Inhibitor | mTOR | Yes | 2009 | Jan 1, 2012 | Dec 31, 2012 | No Longer Used | |
| J9390 | Vinorelbine | Navelbine | 10 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1994 | Jan 1, 1996 | In Use | ||
| NA | Cysteamine Bitartrate | Cystagon | 50mg, 150mg | Chemotherapy | Cystine-Depleting Agent | Yes | 1994 | In Use | ||||
| J9098 | Cytarabine | Cytarabine Liposome | 10 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1999 | Jan 1, 2004 | Jan 1, 2026 | In Use | |
| NA | Abemaciclib | Verzenio | 100 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
| NA | Enasidenib mesylate | Idhifa | 100 mg | Chemotherapy | Enzyme Inhibitor | IDH2 | Yes | 2017 | In Use | |||
| NA | Abemaciclib | Verzenio | 150 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2017 | In Use | |||
| NA | Panobinostat | Farydak | 20 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
| NA | Cyclophosphamide | Cyclophosphamide oral | 50 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1959 | In Use | |||
| NA | olaparib | Lynparza | 50 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2014 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home